Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
11 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
On Thursday, Roivant Sciences (NASDAQ: ROIV ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Roivant Sciences reported a quiet
The clinical-stage biotech said H1 2026 revenue fell to €1.1 million from €2.4 million a year earlier. It also said cash and cash equivalents were €17.1 million at June 30 and runway was estimated to December 2026.
The final terms dated 29 September 2026 say the tranche is issued at US$8.30 and lifts total securities to 177,806,448. The document also names the authorised participants, custodian and paying agent.
The company reported results for the period ended 31 May 2026 and said CEO Jerry Randall intends to retire from the role. It also highlighted revenue growth, a share buyback programme and recent disposals and acquisitions.
Final terms show the tranche of 600,000 securities has an issue price of US$8.35 and brings the series total to 176,062,128 securities. A partial TER waiver applies until 31 December 2026.
Zeppelin Hotel Tech AGby Michael MitterhoferPublic disclosure of inside information according to article 17 MAR Meran (pta/25.09.2026/14:18) - In light of the application for delisting from the Vienna MTF in connection with the planned merger with ReGuest S.p.A. (see the ad hoc announcement of Zepp…
Zeppelin Hotel Tech AGby Michael MitterhoferPublic disclosure of inside information according to article 17 MARZeppelin Hotel Tech AG: Change to the financial calendar — no publication of the half-year report 2026Meran (pta000/25.09.2026/14:18 UTC+2)In light of the application for delisting from th…
For best results when printing this announcement, please click on link below: RNS Number: 0602W India Capital Growth Fund Limited 24 September 2026 INDIA CAPITAL GROWTH FUND LIMITED Interim Results for the six months ended 30 June 2026 24 September 2026, London - India Capital Growth Fund ("ICGF" or "the Company"), the
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv
V-ZUG Holding AG / Key word(s): Miscellaneous Forward-looking succession planning at the helm of V-ZUG 24-Sep-2026 / 06:30 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. ════════════════════════════════════════════════════════════
On Thursday, Immunovant (NASDAQ: IMVT ) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Immunovant reported a quiet